Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Ohaegbulam, Kim C.; Assal, Amer; Lazar-Molnar, Eszter; Yao, Yu; Zang, Xingxing
• Is Part Of: Trends in molecular medicine. Volume 21:Issue 1(2015)
• Page Start: 24
• Page End: 33
• Publication Date: 2015-01
• Subjects: Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; Physiology, Pathological -- Periodicals; 572.8
• DOI: 10.1016/j.molmed.2014.10.009
• Languages: English
• ISSNs: 1471-4914

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">The PD-1/PD-L1 pathway inhibits T cell functions.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">The PD-1/PD-L1 pathway functions as immune evasion in some cancers.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Clinical trials targeting PD-1 and PD-L1 show impressive response rates.</p> </list-item> </list> </p> </sec> </abstract>